Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Preventing and reversing neuroinflammatory brain damage using local expansion of regulatory T cells

Project description

Expanding brain-resident regulatory T cells to combat neurological disorders

Traumatic brain injury, multiple sclerosis and Alzheimer's disease cause inflammatory damage to the brain. Recent evidence indicates the presence of a brain-resident regulatory T cell population secreting anti-inflammatory and reparative proteins that requires Interleukin-2 to expand. Based on this observation, the EU-funded TreatBrainDamage project aims to develop a viral vector system capable of brain-specific expression of Interleukin-2 to specifically expand brain regulatory T cells. Studies on animal models of neuroinflammatory diseases show promising results and amelioration of disease phenotype. The project will undertake all the necessary validation experiments to bring this intervention to the clinic.

Objective

"A proposal to use local IL2 delivery via a viral vector to prevent and reverse the inflammatory damage that happens to the brain during neuroinflammatory diseases as diverse as traumatic brain injury, Multiple Sclerosis and Alzheimer's Disease. In ""TissueTregs"" we identified and characterised a brain-resident regulatory T cell population, with high expression of anti-inflammatory and reparative proteins. A synthetic circuit for deliver IL2 to the brain expanded this population, without any off-target increases in circulation or the blood. In order to translate these findings beyond the scope of the original ""TissueTregs"" grant, we have moved to a viral vector system, designed to give brain-specific expression of IL2. This systems demonstrates long-lasting brain-specific expansion of the brain-resident regulatory T cell population, after only a single intravenous injection. Preliminary results demonstrate a striking ability of this treatment to prevent neurological damage in mouse models of traumatic brain injury and Multiple Sclerosis. A provisional patent has been filed to cover this invention. In this PoC grant, we will run the necessary validation and target deconvolution experiments to pave the way for this treatment to move into the clinical sphere."

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2019-PoC

See all projects funded under this call

Host institution

THE BABRAHAM INSTITUTE
Net EU contribution
€ 150 000,00
Address
Babraham Hall
CB22 3AT Cambridge
United Kingdom
Region
East of England East Anglia Cambridgeshire CC
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)